…
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, and over"the"counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti"inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Nutra Pharma Corp (NPHC) is a micro-cap company quoted on the OTC Pink that states it is involved in development and commercialization of pharmaceutical and nutraceutical products; public disclosures are limited. Long-term growth may depend on successful product development, regulatory approvals and commercialization, and the company may appeal to investors seeking speculative exposure to early-stage healthcare ventures.
Principal risks include limited and irregular public reporting, low liquidity, an unproven product pipeline and significant execution and regulatory uncertainty that could lead to dilution or loss of investment.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Income before tax | -0.77M | -3.88M | -6.59M | -3.88M | -4.03M |
| Net income | -0.77M | -3.88M | -6.59M | -3.88M | -4.03M |
| Selling general administrative | 1.93M | 1.20M | 1.20M | 1.39M | 1.48M |
| Gross profit | 0.01M | 0.01M | 0.03M | 0.01M | 0.09M |
| Reconciled depreciation | 0.06M | 0.07M | 0.08M | 0.01M | 0.01M |
| Ebit | -1.09M | -3.69M | -1.23M | 0.27M | -1.38M |
| Ebitda | -2.11M | -3.69M | -6.25M | -3.29M | -1.38M |
| Depreciation and amortization | -1.03M | 0.01M | - | - | 0.01M |
| Non operating income net other | - | -5.10M | - | 2.15M | - |
| Operating income | -1.09M | -1.88M | -1.23M | -1.88M | -1.38M |
| Other operating expenses | 1.14M | 1.50M | - | - | 1.50M |
| Interest expense | 0.34M | 0.59M | 0.26M | 0.59M | 0.36M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.50M | -0.34M | -0.26M | -0.59M | -0.36M |
| Non recurring | - | 0.06M | - | - | - |
| Income tax expense | -0.76M | -1.42M | - | - | -2.29M |
| Total revenue | 0.05M | 0.13M | 0.10M | -1.88M | 0.12M |
| Total operating expenses | 1.10M | 1.39M | 1.33M | -1.39M | 1.48M |
| Cost of revenue | 0.04M | 0.12M | 0.07M | 2.01M | 0.03M |
| Total other income expense net | 0.32M | -1.92M | -5.10M | -1.42M | -2.29M |
| Net income from continuing ops | -13.10M | -6.59M | -6.59M | -3.88M | -4.03M |
| Net income applicable to common shares | -13.10M | -6.59M | -6.59M | -3.88M | -4.03M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | - | 0.30M | 0.14M | 0.34M | 0.14M |
| Other current assets | - | 0.15M | 0.06M | 0.01M | 0.06M |
| Total liab | - | 11.80M | 6.08M | 12.04M | 6.08M |
| Total stockholder equity | - | -11.49M | -5.94M | -11.70M | -5.94M |
| Other current liab | - | 5.96M | 0.00M | 0.84M | 1.19M |
| Common stock | - | 6.96M | 4.05M | 5.88M | 4.05M |
| Capital stock | - | 7.34M | 6.96M | 5.88M | 4.05M |
| Retained earnings | - | -68.63M | -61.27M | -67.86M | -61.27M |
| Other assets | - | 0.11M | 0.09M | 0.07M | 0.02M |
| Cash | - | -0.14M | -0.22M | 0.00M | 0.00M |
| Total current liabilities | - | 11.48M | 6.03M | 10.99M | 6.03M |
| Current deferred revenue | - | 0.20M | 2.02M | - | - |
| Net debt | - | 5.18M | 3.58M | 8.26M | 3.58M |
| Short term debt | - | 4.73M | 3.53M | - | 3.34M |
| Short long term debt | - | 7.60M | 4.64M | 7.35M | 3.53M |
| Short long term debt total | - | 5.04M | 3.58M | - | - |
| Other stockholder equity | - | 50.18M | 51.29M | - | - |
| Property plant equipment | - | 0.14M | 0.06M | 0.21M | 0.01M |
| Total current assets | - | 0.06M | 0.12M | 0.06M | 0.12M |
| Net tangible assets | - | -20.89M | -11.70M | -11.70M | -5.94M |
| Net receivables | - | 0.04M | 0.02M | 0.03M | 0.02M |
| Long term debt | - | 0.52M | 0.91M | 0.91M | 0.05M |
| Inventory | - | 0.01M | 0.04M | 0.01M | 0.04M |
| Accounts payable | - | 0.60M | 0.48M | 0.58M | 1.49M |
| Common stock total equity | - | - | 5.88M | - | 4.05M |
| Preferred stock total equity | - | - | 0.00M | - | 0.00M |
| Retained earnings total equity | - | - | -67.86M | - | -61.27M |
| Non currrent assets other | - | 0.09M | 0.02M | 0.05M | 0.02M |
| Non current assets total | - | 0.25M | 0.03M | 0.28M | 0.03M |
| Capital lease obligations | - | 0.08M | 0.14M | 0.22M | - |
| Long term debt total | - | - | 0.91M | - | 0.05M |
| Breakdown | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Investments | -0.29M | -0.01M | - | 0.00M | -0.01M |
| Change to liabilities | 0.07M | 0.52M | 0.11M | 0.48M | 0.13M |
| Total cashflows from investing activities | -0.29M | -0.01M | -0.01M | -0.01M | -0.01M |
| Net borrowings | 2.13M | 0.74M | 0.57M | 0.11M | 1.14M |
| Total cash from financing activities | 0.88M | 1.00M | 0.74M | 1.00M | 1.12M |
| Change to operating activities | 0.05M | 0.32M | 0.34M | 0.41M | 0.24M |
| Net income | -0.77M | -3.88M | -6.59M | -3.88M | -4.03M |
| Change in cash | 0.09M | 1.00M | 0.09M | 0.09M | 1.12M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 1.15M | 0.03M |
| End period cash flow | 0.09M | 0.00M | 0.00M | 0.00M | 1.15M |
| Total cash from operating activities | -0.88M | -1.00M | -0.74M | -1.00M | -1.14M |
| Depreciation | 0.07M | 0.01M | 0.08M | 0.38M | 0.01M |
| Other cashflows from investing activities | -0.25M | -0.25M | -0.25M | -0.25M | - |
| Change to inventory | -0.02M | -0.02M | -0.03M | -0.02M | 0.01M |
| Change to account receivables | -0.00M | -0.00M | -0.02M | -0.00M | 0.02M |
| Other cashflows from financing activities | 1.05M | 1.21M | 0.17M | 0.17M | 1.62M |
| Change to netincome | 10.89M | 0.06M | 5.26M | 1.86M | 2.37M |
| Capital expenditures | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Change receivables | - | -0.02M | - | -0.00M | - |
| Cash flows other operating | - | 5.21M | - | 0.17M | - |
| Change in working capital | 0.30M | 0.45M | 0.41M | 0.45M | 0.40M |
| Stock based compensation | 0.01M | 0.07M | 0.07M | - | 0.07M |
| Other non cash items | 1.15M | 2.71M | 0.14M | 0.61M | 2.40M |
| Free cash flow | -0.88M | -1.00M | -0.74M | -1.00M | -1.15M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NPHC Nutra Pharma Corp |
- -% |
0.00 | - | - | 3.07 | - | 35.54 | 1.11 |
| MKKGY Merck KGaA ADR |
0.40 1.22% |
33.13 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.65 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
- -% |
21.64 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.15 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, and over"the"counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti"inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
1537 NW 65th Avenue, Plantation, FL, United States, 33313
954 509 0911
4
| Name | Title | Year Born |
|---|---|---|
| Mr. Erik J. Deitsch | Chairman, CEO, Pres & CFO | 1968 |
| Dr. Dale VanderPutten MBA, Ph.D. | Chief Scientific Officer | 1959 |
| Mr. Neil Roth | Pres of Designer Diagnostics, Inc | NA |
| Ms. Nina Goldstein | Sec. | 1960 |
| Dr. Dale Vander Putten MBA, Ph.D. | Chief Scientific Officer | 1959 |
| Dr. Michael D. Flax D.D.S., M.S., P.A. | CEO, CFO & Chairman | 1956 |
| Joe Lucas | Vice President of Operations | NA |
| Ms. Nina Goldstein | Secretary | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.